

RESEARCH OUTPUTS / RÉSULTATS DE RECHERCHE

Proposition of a new scale for the harmonization and normalization of the nAPCs

Morimont, Laure; Bouvy, Céline; Delvigne, Anne-Sophie; Dogné, Jean-Michel; Douxfils, Jonathan

Publication date:
2019

[Link to publication](#)

Citation for published version (HARVARD):

Morimont, L, Bouvy, C, Delvigne, A-S, Dogné, J-M & Douxfils, J 2019, 'Proposition of a new scale for the harmonization and normalization of the nAPCs: a scientific and regulatory need for clinical studies comparison', 27TH BSTH Annual Meeting, 28/11/19 - 29/11/19.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Proposition of a new scale for the harmonization and normalization of the nAPCsr: a scientific and regulatory need for clinical studies comparison

Laure Morimont^{1,2}, Céline Bouvy¹, Anne-Sophie Delvigne¹, Jean-Michel Dogné², Jonathan Douxfils^{1,2}

¹ Qualiblood s.a., Namur, Belgium

² University of Namur, Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Namur, Belgium



BACKGROUND

- ❖ The evaluation of the activated protein C resistance assay based on the endogenous thrombin potential (ETP-based APCr assay) is requested during the development of steroid contraceptives.¹
- ❖ Results are usually expressed as “normalized APC sensitivity ratio” (nAPCsr) which is the ratio of the patient’s sample on a reference plasma regarding the inhibitory sensitivity of the ETP towards exogenous APC.^{2,3}
- ❖ The reference plasma should achieve near 10% residual ETP in the presence of exogenous APC.
- ❖ However, the use of homemade reference plasma makes the nAPCsr difficult to compare between studies and the impossibility to obtain exactly 10% residual ETP, because of the inter-assay variability, can significantly affect the theoretical 0 to 10 scale of nAPCsr.

AIM

To compare the nAPCsr with this new method for calculation of APC resistance: the nAPCsr₁₀.

METHOD

- ❖ 790 individual plasmas (issued from two sponsored clinical trials) were analyzed to compared their nAPCsr and nAPCsr₁₀
- ❖ Measurements were performed following our validated protocol of the ETP-based APCr assay.
- ❖ A commercially available reference plasma and three levels of quality controls (QCs) were used to validate each experiment.
- ❖ Results were expressed as nAPCsr [▶ equation 1] and as nAPCsr₁₀ [▶ equation 2]

$$\text{nAPCsr} = \frac{\text{Sample ETP (+APC)} / \text{Sample ETP (-APC)}}{\text{Reference plasma ETP (+APC)} / \text{Reference plasma ETP (-APC)}} \quad [\text{equation 1}]$$

$$\text{nAPCsr}_{10} = \frac{\text{Sample residual ETP (\%)}}{10\%} \quad [\text{equation 2}]$$

$$\text{with residual ETP \%} = \frac{\text{Sample ETP (+APC)}}{\text{Sample ETP (-APC)}}$$

RESULTS

A. Test performances

- ❖ Over 86 measurements (38 with batch 1 and 48 with batch 2), no statistically significant difference (p-value>0.05) was observed between the two batches of reference plasma.
- ❖ QCs fitted into their acceptability ranges regardless the batch used but nAPCsr was less reproducible (higher SD) than nAPCsr₁₀. [▶ Table 1]

| | | nAPCsr | | | nAPCsr ₁₀ | | |
|-----------|---------|--------|------|--------------|----------------------|------|-------------|
| | | Mean | SD | 95% CI | Mean | SD | 95% CI |
| QC high | Batch 1 | 8.80 | 0.75 | [7.32-10.28] | 9.37 | 0.27 | [8.85-9.90] |
| | Batch 2 | 8.88 | 0.90 | [7.11-10.64] | 9.39 | 0.23 | [8.94-9.84] |
| QC interm | Batch 1 | 7.51 | 0.49 | [6.55-8.47] | 8.01 | 0.29 | [7.44-8.59] |
| | Batch 2 | 6.46 | 0.49 | [5.50-7.42] | 6.86 | 0.40 | [6.07-7.65] |
| QC low | Batch 1 | 0.00 | / | / | 0.00 | / | / |
| | Batch 2 | 0.00 | / | / | 0.00 | / | / |

TABLE 1: Range values of the nAPCsr and the nAPCsr₁₀ among the two batches of reference plasma on QC high, QC intermediate (QC int.) and QC low. The mean, standard deviation (SD) and 95% confidence interval (=1.96*SD) for each batch on the three levels of QC are shown.

- ❖ Mean inhibition % of the reference plasma (both batches mixed) was 89.30% (SD: 1.03%, 95% CI: [87.29%-91.31%]) and expressed in ratio, it equalled 0.107 (95% CI: 0.087-0.127).
- ❖ Despite a weak variability of the reference plasma, the nAPCsr scale could vary widely.
- ❖ In the case of inhibition % of the reference plasma equalled to 91.8 (maximal tolerated limit in our study [mean inhibition % + 2.5%]), residual ETP ratio would be 0.082. Therefore, nAPCsr scale could go up to 12.2 instead of the maximal value of 10 that is theoretically proposed.

References

- ¹ Guideline on clinical investigation of steroid contraceptives in women - EMEA/CPMP/EWP/519/98 Rev 1.
- ² Nicolaes GA, Thomassen MC, Tans G, Rosing J, Hemker HC. Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC-resistant individuals. *Blood Coagul Fibrinolysis*. 1997; 8: 28-38
- ³ Tripodi A, Chantarangkul V, Negri B, Mannucci PM. Standardization of the APC Resistance Test. Effects of Normalization of Results by Means of Pooled Normal Plasma. *Thromb Haemost*. 1998; 79: 564-6.

Contact : Morimont Laure
laure.morimont@unamur.be
Tel. +3281724292

B. Correlation between nAPCsr and nAPCsr₁₀

- ❖ Wilcoxon signed-rang paired showed a statistically significant difference between nAPCsr and nAPCsr₁₀.
- ❖ Nonetheless, a correlation between nAPCsr and nAPCsr₁₀ was demonstrated with a Spearman correlation (rs) coefficient of 0.99 (95%CI: 0.9880-0.9910; p-value<0.0001).
- ❖ Linear regression showed a slope of 0.93 which denoted 7% downward systematic deviation of nAPCsr compared to nAPCsr₁₀. [▶ Figure 1]




FIGURE 1: Correlation between nAPCsr and nAPCsr₁₀. Spearman correlation coefficient (rs) [95% CI] of 0.9896 [0.9880-0.9910]; p-value<0.0001; r² for linear regression = 0.9704. Linear regression (red straight line) with a slope [95% CI] of 0.9334 [0.9220-0.9448] (blue dotted lines) and Y-intercept of 0.02630.

- ❖ Bland-Altman analysis confirmed our statement that nAPCsr underestimated APC resistance compared to nAPCsr₁₀ with a mean difference (nAPCsr₁₀-nAPCsr) of 5.64% compared to nAPCsr₁₀. [▶ Figure 2]
- ❖ As mean residual ETP ratio of the reference plasma was greater than 0.1 (0.107), when used at the denominator, it gave smaller values than if we had 0.1 at the denominator as for the nAPCsr₁₀.




FIGURE 2: Derived Bland-Altman analysis between nAPCsr and nAPCsr₁₀ for the measurement of APC resistance in plasma samples. Differences (nAPCsr₁₀-nAPCsr) are expressed as a percentage of nAPCsr₁₀. The red dotted line represents the mean difference and blue dotted lines represent 95% IC [=1.96*SD].

CONCLUSION

This is the first study presenting a new scale for the harmonization and normalization of the nAPCsr.

Results revealed a better reproducibility with the nAPCsr₁₀. It avoids the additional variability and the unharmonized scale brought by the use of a reference plasma. Instead, this reference plasma can serve as an additional level of control targeting the desired 10% of residual activity.

This new method and result expression will provide the pharmaceutical industry, the regulatory bodies and the physician, with the opportunity of better reproducibility and harmonization. This will definitely help in study-to-study comparison.

This standardized expression could ease the establishment of thresholds to assess patient’s thrombotic state according to his resistance to APC.

Conflict of Interest :

Jonathan Douxfils reports personal fees from Daiichi Sankyo, Diagnostica Stago, Roche and Roche Diagnostics outside the submitted work. Jonathan Douxfils is CEO and founder of QUALIBlood s.a.

